• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Chimeric T Cell Receptor (chTCR) Production Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

With first-class skills and rich experience, Creative Biolabs offers services for generation and validation of chimeric T cell receptor (chTCR), which is an attractive strategy to genetically modify and redirect the specificity of T cells in adoptive immunotherapy.

Figure, Chimeric T cell receptor. A, Strategies for chTCR; B, A typical chimeric receptor.

Genetically-modified T lymphocytes expressing T cell receptors (chTCR) specific for tumor cells have been widely investigated for cancer therapy. chTCR is an approach that uses the gene encoding modified TCR or monoclonal antibody chains to endow the TCR with high affinity to tumor associated antigens (TAAs). Typically, chTCR consists of three functional regions: extracellular domains, transmembrane domains and intracellular signaling domains. The extracellular fragments made from TCR or tumor-specific antibody are designed to recognize and bind target cells such as cancer cells. As shown in the figure A, the TCR can be conventional or a single chain and the specific antibody can be Fab or single-chain variable fragment (scFv). ScFv is used more frequently than Fab in recent researches. Transmembrane domain is important to overcome the mispairing of chTCR with endogenous TCR chains. To proliferate and respond on an antigen, T cells relies on the co-stimulatory signals. Accordingly, the transmembrane and intracellular signaling domains may be derived from primary activation molecules, co-stimulatory molecules and intracellular protein kinases, such as CD3ζ or FcεRI. A hinge is constructed for linking the extracellular fragments and signaling domains. Additionally, the modification of primary human T cells from healthy donors could be used to generate humanized chTCR (hchTCR) specific for adoptive T cell immunotherapy for cancers. As the chTCR is not restricted by MHC molecules which natural TCR depends on the generated supernatural T cells can be an ideal tool in cancer therapy.

Creative Biolabs have professional experts from different disciplines to ensure the construction of robust and reliable chimeric receptors targeting your concerned antigens.

Regerences:

1. Andreas Hombach, et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb; 16(2):77-87.
2. Kershaw MH, et al. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat rev Immunol. 2005 Dec; 5 (12): 928-40.
3. Dong Wang, et al. Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells. Biotechnol Lett. 2012 Jul; 34(7):1193-201.

To discuss your demands or to request a proposal, please contact us by .